Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BIOANASDAQ:DAWNNASDAQ:EOLSNASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOA(BIOA)$4.34-6.5%$0.00$2.88▼$26.62$161.32MN/A469,247 shs512,188 shsDAWNDay One Biopharmaceuticals$6.32-1.4%$6.84$6.08▼$16.76$649.73M-1.31.13 million shs1.50 million shsEOLSEvolus$9.28-0.2%$10.27$8.67▼$17.82$599.62M1749,941 shs712,649 shsTRVITrevi Therapeutics$5.96-1.8%$6.37$2.36▼$7.48$711.97M0.591.38 million shs3.29 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOA(BIOA)-0.80%-4.30%+11.00%-3.28%+33,806.25%DAWNDay One Biopharmaceuticals-1.40%-5.25%+0.48%-23.21%-52.80%EOLSEvolus-0.22%-6.55%-3.23%-28.78%-12.78%TRVITrevi Therapeutics-1.81%-2.13%-3.56%-7.88%+121.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIOA(BIOA)N/AN/AN/AN/AN/AN/AN/AN/ADAWNDay One Biopharmaceuticals1.6773 of 5 stars3.60.00.00.02.32.50.0EOLSEvolus3.9044 of 5 stars3.51.00.03.51.83.30.6TRVITrevi Therapeutics2.3672 of 5 stars3.72.00.00.01.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOA(BIOA) 1.75Reduce$5.6730.57% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57383.73% UpsideEOLSEvolus 3.00Buy$23.75155.93% UpsideTRVITrevi Therapeutics 3.33Buy$20.29240.36% UpsideCurrent Analyst Ratings BreakdownLatest BIOA, DAWN, TRVI, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/2/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.005/28/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.005/20/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.005/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOA(BIOA)N/AN/AN/AN/AN/AN/ADAWNDay One Biopharmaceuticals$131.16M4.88N/AN/A$4.99 per share1.27EOLSEvolus$266.27M2.25N/AN/A$0.09 per share103.11TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOA(BIOA)N/AN/A0.00N/AN/AN/AN/AN/AN/ADAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/8/2025 (Estimated)EOLSEvolus-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.45N/AN/AN/AN/A-58.41%-52.52%8/6/2025 (Estimated)Latest BIOA, DAWN, TRVI, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOA(BIOA)N/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOA(BIOA)N/AN/AN/ADAWNDay One BiopharmaceuticalsN/A10.6210.55EOLSEvolus22.002.342.16TRVITrevi TherapeuticsN/A15.3815.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOA(BIOA)N/ADAWNDay One Biopharmaceuticals87.95%EOLSEvolus90.69%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipBIOA(BIOA)N/ADAWNDay One Biopharmaceuticals6.20%EOLSEvolus5.90%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOA(BIOA)N/A35.85 millionN/ANot OptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionableEOLSEvolus17064.48 million60.67 millionOptionableTRVITrevi Therapeutics20117.29 million95.83 millionOptionableBIOA, DAWN, TRVI, and EOLS HeadlinesRecent News About These CompaniesTrevi Therapeutics Stockholders Approve Key AmendmentsJune 17, 2025 | tipranks.comQ2 EPS Estimate for Trevi Therapeutics Lifted by AnalystJune 15, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Forecast for TRVI Q2 EarningsJune 13, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?June 9, 2025 | marketbeat.comTwo Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)June 9, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLCJune 7, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenJune 7, 2025 | marketbeat.comTrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 5, 2025 | prnewswire.comAmeriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)June 5, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comTrevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockJune 3, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's WhyJune 3, 2025 | marketbeat.comTrevi Therapeutics Announces Proposed Public Offering of Common StockJune 2, 2025 | prnewswire.comTrevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease PatientsJune 2, 2025 | benzinga.comTrevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?June 2, 2025 | marketbeat.comTrevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral CapitalJune 2, 2025 | marketbeat.comTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 2, 2025 | prnewswire.comTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 1, 2025 | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by AnalystsJune 1, 2025 | marketbeat.comResearch Analysts Issue Forecasts for TRVI Q2 EarningsMay 31, 2025 | marketbeat.comH.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy RatingMay 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOA, DAWN, TRVI, and EOLS Company Descriptions(BIOA) NYSE:BIOABioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.Day One Biopharmaceuticals NASDAQ:DAWN$6.32 -0.09 (-1.40%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.32 0.00 (0.00%) As of 06/20/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Evolus NASDAQ:EOLS$9.28 -0.02 (-0.22%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.27 -0.01 (-0.11%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Trevi Therapeutics NASDAQ:TRVI$5.96 -0.11 (-1.81%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.96 0.00 (-0.08%) As of 06/20/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
